chartexchange

Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?

The Motley Fool | Nov 21, 2026 5:15 PM EST

Shares of Novo Nordisk (NYSE:NVO) have fallen 70% from the all-time highs reached after it launched the first GLP-1 weight-loss shot. That has pushed the dividend yield up to 4.5%, well above the pharmaceutical industry average of 1.3%, despite a strong payout ratio of roughly 33%. Wall Street may not be giving Novo Nordisk enough credit, especially given the strength of its new GLP-1 pill. Here's why more aggressive investors may want to jump on this high-yield opportunity. Image source: Novo Nordisk. Continue reading

Read original article